Current Headlines

  1. Archeus Technologies Receives FDA Clearance Of Investigational New Drug Application For ART-101 In Development For The Treatment Of Prostate Cancer 6/20/2025

    Archeus Technologies, a company developing radiopharmaceutical therapies for the treatment of patients with cancer, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for ART-101, a novel receptor-based targeting small molecule that Archeus has developed for the imaging and treatment of prostate cancer.

  2. Pattern To Test Novel AI-Discovered Molecular De Novo Drug For Treatment Of Multiple Hard-To-Treat Cancers 6/18/2025

    Pattern Computer®, Inc. (“Pattern” or “the Company”), the global leader in Pattern Discovery, today announced that the Company is beginning testing of its AI-discovered (de novo) drug for the treatment of multiple hard-to-treat cancers.

  3. Lisata Therapeutics And GATC Health Expand Relationship To Advance AI-Driven Drug Discovery And Development 6/17/2025

    Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, and GATC Health Corp. (“GATC”), a leading tech-bio company leveraging artificial intelligence (AI) to transform drug discovery and development, today announced a strategic alliance designed to accelerate and improve the success rate of the traditional drug development process.

  4. ArkBio's New Drug Application For ADHD Therapeutic Azstarys Accepted And Granted Priority Review By China NMPA 6/16/2025

    Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that the National Medical Products Administration (NMPA) has officially accepted its New Drug Application (NDA) for Azstarys (serdexmethylphenidate/dexmethylphenidate extended-release capsules) and granted it Priority Review designation.

  5. Singota Solutions Opens New European Facility 6/16/2025

    Bloomington-based Singota Solutions is expanding its international footprint with the opening of its second pharmaceutical storage facility in Switzerland.

  6. Circle Pharma Receives FDA Orphan Drug Designation For CID-078 For The Treatment Of Small Cell Lung Cancer 6/16/2025

    Circle Pharma, a clinical-stage biopharmaceutical company advancing macrocycle therapeutics for difficult-to-treat cancers, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to CID-078 for the treatment of small cell lung cancer (SCLC).

  7. Fauna Bio Launches Fauna Brain AI Platform To Accelerate Drug Discovery Inspired By Nature's Most Resilient Species 6/16/2025

    Fauna Bio, a biotechnology company harnessing animal genomics to improve human health, today announced the launch of Fauna Brain, a proprietary AI platform designed to accelerate target discovery and streamline early-stage R&D.

  8. NextCure And Simcere Zaiming Announce Strategic Partnership For A Novel Antibody-Drug Conjugate Targeting CDH6 6/16/2025

    NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, and Simcere Zaiming, an oncology-focused biopharmaceutical company and a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096), today announced a strategic partnership to develop SIM0505, a novel antibody-drug conjugate (ADC) targeting CDH6 (cadherin-6 or K-cadherin) for the treatment of solid tumors.

  9. Aquestive Therapeutics Announces FDA Acceptance Of New Drug Application And PDUFA Date For Anaphylm™ For The Treatment Of Severe Allergic Reactions 6/16/2025

    Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company’s New Drug Application (NDA) for Anaphylm™ in the treatment of Type 1 allergic reactions, including anaphylaxis, and has assigned a Prescription Drug User Fee Act (PDUFA) target action date of January 31, 2026.

  10. BioAro Launches PanOmiQ™ Research In Breakthrough For AI-Driven Drug Discovery And Multi-Omics 6/16/2025

    BIO International Convention In a bold move that may redefine the global future of genomics, drug discovery, and precision health, BioAro Inc., a Canadian biotechnology and precision medicine company, unveiled its expanded PanOmiQ™ platform today at the 2025 BIO International Convention in Boston.